

**Oklahoma Health Care Authority**  
**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – December 8, 2010 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. November 10, 2010 DUR Minutes – Vote
  - B. November 11, 2010 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for October 2010
  - B. Retrospective Drug Utilization Review Response for August 2010
  - C. Medication Coverage Activity Audit for November 2010
  - D. Pharmacy Help Desk Activity Audit for November 2010

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

- 5. Action Item – Vote to Prior Authorize Metozolv ODT<sup>®</sup> – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Alzheimer’s Medications – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Singulair<sup>®</sup> and 30 Day Notice to Prior Authorize Zflo CR<sup>®</sup> – See Appendix E.**
  - A. Introduction
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. **Action Item – Post-Implementation Utilization Review of Atypical Antipsychotics and 30 Day Notice to Prior Authorize Latuda<sup>™</sup> – See Appendix F.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorizations Review
  - D. Behavioral Health Data
  - E. Metabolic Monitoring Questionnaires
  - F. COP Recommendations
  - G. Utilization Details
  - H. Latuda<sup>™</sup> Product Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

9. **60 Day Notice to Prior Authorize Benign Prostate Hyperplasia (BPH) Products – See Appendix G.**
  - A. Utilization Review
  - B. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
  
11. **Future Business**
  - A. Annual Review of Advair<sup>®</sup> / Symbicort<sup>®</sup>
  - B. Annual Review of Antihypertensives
  - C. Annual Review of Hypnotics
  - D. New Product Reviews

12. **Adjournment**